ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytes.
LP-BM5 MuLV infection of monocyte-macrophages (MM cells) and the ability of MM cells infected with this murine oncornavirus complex to transmit murine acquired immune deficiency syndrome (MAIDS) were assessed. Adherent cells expressing Mac-1 antigen (Mac-1+) were isolated from the peritoneum of infected C57BL/6 mice at weekly intervals postinoculation. A small percentage of MM cells was infected by 7 days after inoculation with LP-BM5 MuLV and virus production could be detected in MM cells throughout the course of disease. MAIDS could be induced in naive C57BL/6 mice by i.p. injection of 0.5-3 x 10(5) MM cells derived from infected mice as early as 8 weeks postinfection. When 3 x 10(5) cells (300 infectious centers) were injected, the progression of disease was similar to that seen after inoculation with a known virus pool (log10 5.78 XC pfu/ml). Treatment with zidovudine (ZDV) at 1 mg/ml in drinking water delayed disease progression if started 24 h prior to inoculation of MM cells and given continuously.
Bilello
J A
JA
University of Maryland Cancer Center, Baltimore, Maryland 21201.
Kort
J J
JJ
MacAuley
C
C
Fredrickson
T N
TN
Yetter
R A
RA
Eiseman
J L
JL
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002478:Cells, Cultured; D005260:Female; D007075:Immunoglobulin M / Q000097:blood; D009052:Leukemia Virus, Murine / Q000187:drug effects / Q000502:physiology*; D008264:Macrophages / Q000382:microbiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000382:microbiology*; D016183:Murine Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology / Q000635:transmission*; D013997:Time Factors; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000627:therapeutic use*
D000914:Antibodies, Viral; D007075:Immunoglobulin M; D015215:Zidovudine